Relevance of c-erbB2, PLU-1 and survivin mRNA expression to diagnostic assessment of breast cancer

Anticancer Research

Volumn 22, Issue 5, 2002, Pages 2965-2969

  Izawa, Akiko ^a   Kobayashi, Daisuke ^a   Nasu, Shunichi ^a   Saito, Kaori ^a   Moriai, Ryosuke ^a   Asanuma, Koichi ^a   Nakamura, Masashi ^a   Yagihashi, Atsuhito ^a   Watanabe, Naoki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; Gene expression; Quantification; Survivin

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; ONCOPROTEIN; PROTEIN PLU1; SURVIVIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; INTRADUCTAL CARCINOMA; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE DIAGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS;

ADULT; AGED; BREAST NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; RECEPTOR, ERBB-2; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 0036765423     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Mckenzie SJ: Diagnostic utility of oncogenes and their products in human cancer. Biochim Biophys Acta 1072: 193-214, 1991.
2. Persons DL, Borelli KA and Hsu PH: Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod Pathol 10: 720-727, 1997.
3. Carneiro F and Sobrinho-Simoes M: The prognostic significance of amplification and overexpression of c-met and c-erbB-2 in human gastric carcinomas. Cancer 88: 238-240, 2000.
4. Schneider PM, Praeuer HW, Stoeltzing O, Boehm J, Manning J, Metzger R, Fink U, Wegerer S, Hoelscher AH and Roth JA: Multiple molecular marker testing (p53, c-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer. Br J Cancer 83: 473-479, 2000.
5. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T and Toyoshima K: Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 319: 230-234, 1986.
6. Menard S, Tagliabue E, Campiglio M and Pupa SM: Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol 182: 150-162, 2000.
7. Parkes HC, Lillycrop K, Howell A and Craig RK: C-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosis. Br J Cancer 61: 39-45, 1990.
8. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
9. Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD and Miles DW: Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 79: 1220-1226, 1999.
10. Lu PJ, Sundquist K, Baeckstrom D, Poulsom R, Hanby A, Meier-Ewert S, Jones T, Mitchell M, Pitha-Rowe P, Freemont P and Taylor-Papadimitriou J: A novel gene (PLU-1) containing highly conserved putative DNA/chromatin binding motifs is specifically up-regulated in breast cancer. J Biol Chem 274: 15633-15645, 1999.
11. Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921, 1997.
12. Swana HS, Grossman D, Anthony JN, Weiss RM and Altieri DC: Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. New Eng J Med 341: 452-453, 1999.
13. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T and Reed JC: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), bax, caspases, and anticancer drugs. Cancer Res 58: 5315-5320, 1998.
14. Yajima T, Yagihashi A, Kameshima H, Kobayashi D, Furuya D, Hirata K and Watanabe N: Quantitative reverse transcription-PCR assay of the RNA component of human telomerase using the TaqMan fluorogenic detection system. Clin Chem 44: 2441-2445, 1998.
15. Yajima T; Yagihashi A, Kameshima H, Furuya D, Kobayashi D, Hirata K and Watanabe N: Establishment of quantitative reverse transcription-polymerase chain reaction assays for human telomerase-associated genes. Clin Chim Acta 290: 117-127, 2000.
16. The Japanese Breast Cancer Society. General Rules for Clinical and Pathological Recording of Breast Cancer, Ed. 12, Tokyo, Kanehara Public Co., 1996.
17. Mahotka C, Winzel M, Springer E, Gabbert HE and Gerharz CD: Survivin-AEx3 and survivin-2B: Two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 59: 6097-6102, 1999.
18. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M and Tanigawa N: Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6: 127-134, 2000.
19. Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D and Watanabe N: Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 91: 1204-1209, 2000.
20. Nicolini A, Colombini C, Luciani L, Carpi A and Giuliani L: Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. Br J Cancer 64: 154-158, 1991.
21. Villena V, Lopez-Encuentra A, Echave-Sustaeta J, Martin-Escribano P, Ortuno-de-Solo B and Estenoz-Alfaro J: Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. A study of 207 patients. Cancer 15: 736-740, 1996.